Key points from article :
A new article reports that New York–based brain-computer interface (BCI) company Synchron has raised $200 million in Series D funding, bringing its total to $345 million. The round was led by Double Point Ventures, with contributions from long-standing backers such as ARCH Ventures and Khosla Ventures, as well as new investors including Australia’s National Reconstruction Fund and the Qatar Investment Authority. The article does not cite a journal and is reported as news.
Synchron is developing the Stentrode, a minimally invasive BCI that can be implanted via blood vessels rather than open-brain surgery. Once positioned next to the motor cortex, it records neural activity and converts these signals into digital commands. Early trials in Australia and the U.S. have implanted the device in 10 people with paralysis, enabling hands-free control of digital devices such as computers and tablets.
The new funding will support expanded trials, commercialization, and growth of the company’s internal hubs: a cognitive AI division in New York to train models on brain data, and an engineering centre in San Diego. CEO and founder Tom Oxley says the investment will also accelerate work on a next-generation, high-channel whole-brain interface.
The article places the raise in the context of Synchron’s growing momentum. The company has secured progressively larger funding rounds since 2017, and its technology recently enabled Mark Jackson, an ALS patient in the FDA-approved COMMAND trial, to operate an iPad using only his thoughts. Synchron has also reached native integration with Apple’s neural interface standards, paving the way for broader assistive-technology adoption, and is collaborating with NVIDIA to improve on-device AI for its implantable systems.
